What is the latest news on MTRI?

In the last 30 days Quantisnow tracked 18 wire items for MTRI: 15 insider trades and 3 13D/G filings. The most recent was published on November 13, 2026.

No. Mentari Therapeutics Inc. reported a net loss of $13.16M for the twelve months ended Sep 30, 2026.

How much cash and debt does MTRI have?

Mentari Therapeutics Inc. reported $1.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.

Where does MTRI stock trade?

Mentari Therapeutics Inc. (MTRI) is listed on NASDAQ.

What sector and industry is MTRI in?

Mentari Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

What companies are similar to MTRI?

Notable peers in the same industry include VNDA (Vanda Pharmaceuticals Inc.), CORT (Corcept Therapeutics Incorporated), AVXL (Anavex Life Sciences Corp.), AXSM (Axsome Therapeutics Inc.). Compare MTRI side-by-side with any of them on Quantisnow.

How can I track MTRI on Quantisnow?

Quantisnow aggregates Mentari Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTRI to receive live email and push alerts on every new disclosure.

MTRI

NASDAQ

Mentari Therapeutics Inc.

SectorHealth Care IndustryBiotechnology: Pharmaceutical Preparations

Follow + get alerts

Website

Mentari Therapeutics Inc. (MTRI) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 18 wire items for MTRI, including 15 insider trades and 3 13D/G filings. The most recent was published Nov 13, 2026.

The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

Price$18.35+3.46 (+23.24%)

02:45 PM08:45 PM

Financial highlights

Full financials

Net income, TTM: -$13.16M
Cash: $1.09M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks18+100%

2026-05-172026-11-08

Mix1890d

Insider15(83%)
13D/G3(17%)

Activity · 52 weeks182 active days

Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

18 items

MTRI FAQ

8 questions

What does Mentari Therapeutics Inc. do?
The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
What is the latest news on MTRI?
In the last 30 days Quantisnow tracked 18 wire items for MTRI: 15 insider trades and 3 13D/G filings. The most recent was published on November 13, 2026.
Is MTRI profitable?
No. Mentari Therapeutics Inc. reported a net loss of $13.16M for the twelve months ended Sep 30, 2026.
How much cash and debt does MTRI have?
Mentari Therapeutics Inc. reported $1.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.
Where does MTRI stock trade?
Mentari Therapeutics Inc. (MTRI) is listed on NASDAQ.
What sector and industry is MTRI in?
Mentari Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
What companies are similar to MTRI?
Notable peers in the same industry include VNDA (Vanda Pharmaceuticals Inc.), CORT (Corcept Therapeutics Incorporated), AVXL (Anavex Life Sciences Corp.), AXSM (Axsome Therapeutics Inc.). Compare MTRI side-by-side with any of them on Quantisnow.
How can I track MTRI on Quantisnow?
Quantisnow aggregates Mentari Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTRI to receive live email and push alerts on every new disclosure.